NASDAQ · AMGN
Healthcare · Drug Manufacturers - General
$375.65
Down-$5.85 (-1.53%)
Updated Sep 16, 2026, 12:50 PM
SID Score
6.5/10
Composite research score
Smart Money
51/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
AMGN closed at $375.65 after 20 trading sessions, down 11.67% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $380.23 | $381.04 | $375.15 | $375.65 | 2.61M |
| Sep 14, 2026 | $381.94 | $384.61 | $376.76 | $381.50 | 2.71M |
| Sep 11, 2026 | $386.135 | $386.99 | $377.22 | $377.35 | 2.27M |
| Sep 10, 2026 | $387.84 | $391.666 | $381.51 | $382.47 | 3.43M |
| Sep 9, 2026 | $393.065 | $395.55 | $389.28 | $391.27 | 2.92M |
| Sep 8, 2026 | $408.90 | $410.025 | $391.17 | $393.17 | 6.83M |
| Sep 4, 2026 | $437.03 | $441.85 | $435.00 | $437.23 | 1.66M |
| Sep 3, 2026 | $445.67 | $445.815 | $438.0801 | $444.12 | 1.84M |
| Sep 2, 2026 | $440.65 | $445.57 | $435.00 | $442.84 | 2.29M |
| Sep 1, 2026 | $435.301 | $438.65 | $431.00 | $438.12 | 2.36M |
| Aug 31, 2026 | $428.59 | $431.85 | $426.00 | $429.88 | 2.34M |
| Aug 28, 2026 | $437.89 | $437.89 | $430.72 | $432.42 | 1.74M |
| Aug 27, 2026 | $433.08 | $442.13 | $431.01 | $436.99 | 1.76M |
| Aug 26, 2026 | $441.00 | $442.885 | $438.24 | $440.34 | 2.29M |
| Aug 25, 2026 | $443.26 | $447.03 | $441.26 | $442.24 | 2.1M |
| Aug 24, 2026 | $440.31 | $445.87 | $435.51 | $443.84 | 2.46M |
| Aug 21, 2026 | $431.72 | $440.51 | $429.38 | $439.33 | 2.11M |
| Aug 20, 2026 | $435.78 | $441.34 | $431.07 | $433.73 | 2.91M |
| Aug 19, 2026 | $430.24 | $443.20 | $429.38 | $442.36 | 2.54M |
| Aug 18, 2026 | $421.64 | $427.39 | $420.72 | $425.28 | 2.59M |
The latest Smart Investors Daily articles mentioning AMGN.
AMGN research
Company profile and research snapshot.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HSBC | Hold | — |
| Sep 8, 2026 | BMO Capital | Market Perform | — |
| Sep 8, 2026 | Cantor Fitzgerald | Neutral | — |
| Sep 4, 2026 | Wells Fargo | Equal-Weight | — |
| Aug 20, 2026 | Piper Sandler | Overweight | — |
Generated Sep 15, 2026, 9:01 PM
Amgen shares declined 1.53% today amid a broader market sentiment shift toward defensive positioning as consumer confidence weakens and the Fed signals potential rate hikes ahead. While the company continues to generate operational momentum with regulatory wins and strategic technology implementations, macro headwinds are weighing on biotech valuations more broadly.
Bottom line: Amgen's modest 1.53% decline appears driven by macro market concerns rather than company-specific negative developments, with the IMDELLTRA® approval actually representing a positive catalyst. Investors should view this pullback as a potential entry point for a defensive healthcare position, though broader Fed policy risks and competitive pressures warrant continued monitoring.
Yahoo · Sep 16, 2026
Amgen (NASDAQ:AMGN) outlined its growth priorities, late-stage pipeline progress and capital-allocation framework during a Morgan Stanley conference, as newly appointed Chief Financial Officer Thomas Dittrich emphasized execution, financial discipline and cash-on-cash returns. Dittrich, who previou
SeekingAlpha · Sep 15, 2026
Amgen Inc. (AMGN) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 11:30 AM EDTCompany ParticipantsThomas J.
Yahoo · Sep 15, 2026
ADM, COCO, AMGN and CNC offer defensive exposure as inflation, oil prices and weak consumer sentiment fuel market volatility.
Yahoo · Sep 15, 2026
Veeva Systems (NYSE: VEEV) today announced that Amgen plans to deploy Veeva Vault CRM globally, building on a collaboration spanning more than a decade.
Interpretive context generated from the platform’s current data sources.
Amgen Inc. shares closed at $375.65, reflecting a single-session decline of approximately 2.50%, per SID market data. Over the trailing one-month period, the stock has fallen 9.53%, though it retains gains of 7.17% over three months and 18.36% over the past twelve months. Technically, AMGN is trading well below its 50-day moving average of $399.43, a gap of roughly 5.9%, while remaining above its 200-day moving average of $366.60, according to Massive/Polygon data. The 14-day relative strength index registers at 17.8, placing the stock firmly in oversold territory—substantially below the conventional 30 threshold. Amgen's beta of 0.472 indicates significantly lower volatility relative to the broader market, consistent with its defensive healthcare positioning. Average daily trading volume stands at approximately 2.89 million shares, and the company's market capitalization is approximately $209.2 billion.
Amgen Inc. currently trades at a price-to-earnings ratio of 27.13, per SID market data, reflecting a premium valuation relative to many large-cap healthcare peers. The PEG ratio stands at 2.72, suggesting that the stock's earnings multiple is elevated relative to its projected growth rate, according to consensus estimates. The price-to-book ratio of 24.16 is notably high, a characteristic common among biotechnology companies with significant intangible assets and intellectual property not fully captured on the balance sheet. Amgen offers a dividend yield of approximately 2.49%, providing meaningful income for shareholders, per SEC filings. This yield positions the company favorably among large-cap biotech firms, many of which do not pay dividends at all. With a market capitalization of $209.2 billion, Amgen ranks among the largest biotechnology companies globally. These valuation metrics collectively reflect the market's pricing of Amgen's established revenue base alongside its growth trajectory.
Amgen Inc. carries a composite smart money score of 51, signaling a neutral positioning among sophisticated market participants, per SID market data. Institutional ownership strength scores a perfect 25 out of 25, indicating robust conviction among large fund managers, according to 13F institutional filings. Insider activity scores 8.6 out of 25, with 15 insider transactions recorded over the past 90 days—comprising 9 purchases and 6 sales, per SEC Form 4 filings. The net buying trend among insiders suggests moderate confidence from company executives, though the overall insider score remains below average. Dark pool activity registers at 10.5 out of 25, indicating moderate but not exceptional off-exchange trading interest. Congressional trading activity scores 6.8 out of 25, reflecting limited but present legislative trading exposure. The divergence between the strong institutional score and weaker insider and dark pool metrics results in the overall neutral composite reading, suggesting no decisive directional consensus among smart money participants at current price levels.
Amgen Inc. has delivered three consecutive quarters of earnings beats, according to company earnings reports. In the most recent reported quarter, the company posted earnings per share of $6.29 against analyst estimates of $5.60, representing a positive surprise of $0.69, or approximately 12.3%. The prior quarter produced EPS of $5.15 versus the $4.76 consensus estimate, a beat of $0.39. The quarter before that saw actual EPS of $5.29 compared to the $4.75 estimate, a positive surprise of $0.54. This consistent pattern of outperformance reflects disciplined cost management and revenue execution. Looking ahead, analysts project fourth-quarter earnings of approximately $4.81 per share, per analyst estimates, with results expected in early 2026. The sequential decline in the estimate relative to the most recent actual result of $6.29 reflects typical quarterly seasonality in Amgen's revenue mix across its diversified portfolio of therapeutic products.
Wall Street sentiment toward Amgen Inc. has shifted incrementally bearish in recent weeks, per SID consensus data. On September 10, HSBC downgraded the stock from Buy to Hold, and on September 8, BMO Capital lowered its rating from Outperform to Market Perform, according to Wall Street analyst reports. On the same date, Cantor Fitzgerald reiterated its Neutral stance. Wells Fargo maintained its Equal-Weight rating on September 4, while Piper Sandler held its Overweight rating on August 20. The recent activity reflects two notable downgrades among the five most recent actions, with no upgrades recorded during this period. The emerging consensus leans toward a neutral-to-cautious stance, with three of the five most recent ratings effectively at hold-equivalent levels. Piper Sandler remains the sole bullish outlier among recent coverage updates. These rating adjustments coincide with the stock's decline below its 50-day moving average and its oversold RSI reading of 17.8.
The latest Smart Investors Daily articles mentioning AMGN.
